ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cell-signalling molecules"

  • Abstract Number: 0282 • ACR Convergence 2020

    Expression of the cGAMP Transporter SLC19A1 Is Altered in Systemic Lupus Erythematosus

    Jeong Min Yu1, Gantsetseg Tumurkhuu2, Erica Montano2, Gabriela de los Santos2, Daniel J Wallace2, Mariko Ishimori3 and Caroline Jefferies1, 1Cedars-Sinai Medical Center, West Hollywood, CA, 2Cedars-Sinai Medical Center, Los Angeles, 3Cedars-Sinai Medical Center, Los Angeles, CA

    Background/Purpose: Inappropriate sensing of nucleic acids leading to enhanced type I interferon (IFN) induction is a hallmark of SLE, contributing to breakdown of immune tolerance…
  • Abstract Number: 0292 • ACR Convergence 2020

    Exhausted pSTAT5-IFNα Signaling Pathways in SLE Patients Are Correlated with Age-associated B Cells and Disease Activity

    Samantha Slight-Webb1, Miles Smith2, Kevin Thomas1, Susan Macwana1, Holden Maecker3, Paul Utz4, Judith James5 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, 3Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, 4Stanford University School of Medicine, Stanford, CA, 5Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by periods of elevated and suppressed clinical symptoms. Specific cell subsets, such as CD11c+ age-associated…
  • Abstract Number: 0304 • ACR Convergence 2020

    Type I Interferon Inhibits Glucocorticoid-Induced Leucine Zipper (GILZ) Expression and Upregulation by Glucocorticoids

    Wendy Dankers1, Melissa Northcott2, Taylah Bennett3, Brendan Russ3, Jacqueline Flynn1, Sarah Jones2 and Eric Morand1, 1Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 2Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, 3Department of Microbiology, Monash University, Melbourne, Australia

    Background/Purpose: Glucocorticoids (GC) are broadly used in the treatment of inflammatory diseases, including systemic lupus erythematosus (SLE). Despite their widespread use, most SLE patients do…
  • Abstract Number: 0461 • ACR Convergence 2020

    High-Throughput Single-Cell Analysis Reveals Unique Lung Cellular Subsets in a Murine Model of Rheumatoid Arthritis-Inflammatory Lung Disease

    Rohit Gaurav1, Ted Mikuls1, Geoffrey Thiele1, Amy Nelson1, Meng Niu1, Chittibabu Guda1, James Eudy1, Austin Barry1, Debra Romberger1, Michael Duryee1, Bryant England1 and Jill Poole1, 1University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis (RA)-associated inflammatory lung disease is an extra-articular manifestation of RA associated with increased morbidity and mortality, whose precise molecular mechanisms remain undetermined.…
  • « Previous Page
  • 1
  • 2
  • 3
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology